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Abstract
Here we describe a chemical biology strategy performed in Staphylococcus aureus and
Staphylococcus epidermidis to identify MnaA, a 2-epimerase that we demonstrate intercon-
verts UDP-GlcNAc and UDP-ManNAc to modulate substrate levels of TarO and TarA wall
teichoic acid (WTA) biosynthesis enzymes. Genetic inactivation ofmnaA results in com-
plete loss of WTA and dramatic in vitro β-lactam hypersensitivity in methicillin-resistant S.
aureus (MRSA) and S. epidermidis (MRSE). Likewise, the β-lactam antibiotic imipenem
exhibits restored bactericidal activity againstmnaAmutants in vitro and concomitant effi-
cacy against 2-epimerase defective strains in a mouse thigh model of MRSA and MRSE
infection. Interestingly, whereas MnaA serves as the sole 2-epimerase required for WTA
biosynthesis in S. epidermidis, MnaA and Cap5P provide compensatory WTA functional
roles in S. aureus. We also demonstrate that MnaA and other enzymes of WTA biosynthesis
are required for biofilm formation in MRSA and MRSE. We further determine the 1.9Å crys-
tal structure of S. aureusMnaA and identify critical residues for enzymatic dimerization, sta-
bility, and substrate binding. Finally, the natural product antibiotic tunicamycin is shown to
physically bind MnaA and Cap5P and inhibit 2-epimerase activity, demonstrating that it
inhibits a previously unanticipated step in WTA biosynthesis. In summary, MnaA serves as
a new Staphylococcal antibiotic target with cognate inhibitors predicted to possess dual
therapeutic benefit: as combination agents to restore β-lactam efficacy against MRSA and
MRSE and as non-bioactive prophylactic agents to prevent Staphylococcal biofilm
formation.
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Author Summary
Staphylococcus aureus and Staphylococcus epidermidis cause life-threatening infections
that are commonly acquired in hospitals as well as the community and remain difficult to
treat with current antibiotics. In part, this is due to the emergence of methicillin-resistant
S. aureus and S. epidermidis (MRSA and MRSE), which exhibit broad resistance to β-lac-
tams such as penicillin and other members of this important founding class of antibiotics.
Compounding this problem, Staphylococci commonly colonize the surface of catheters
and other medical devices, forming bacterial communities that are intrinsically resistant to
antibiotics. Here we functionally characterize a family of 2-epimerases, named MnaA and
Cap5P, that we demonstrate by genetic, biochemical, and X-ray crystallography means are
essential for wall teichoic acid biosynthesis and that upon their genetic inactivation render
methicillin-resistant Staphylococci unable to form biofilms as well as broadly hypersuscep-
tible to β-lactam antibiotics both in vitro and in a host infection setting. WTA 2-epimer-
ases therefore constitute a novel class of methicillin-resistant Staphylococcal drug targets.
Introduction
Staphylococcus aureus is a leading cause of hospital and community-acquired infections by
Gram-positive bacteria [1–3] and Staphylococcus epidermidis has emerged as the most com-
mon cause of biofilm infections on medical implant devices [4]. In large part, the difficulty in
treating these infections lies in their broad resistance to β-lactams, an otherwise powerful class
of antibiotics that include methicillin, penicillin, cephalosporins and carbapenems such as imi-
penem [5]. Mechanistically, β-lactams are bactericidal agents that lyse cells by inhibiting peni-
cillin binding proteins (PBPs) involved in peptidoglycan (PG) synthesis and cross-linking in
the cell wall [5, 6]. Methicillin-resistant strains of S. aureus (MRSA) and S. epidermidis
(MRSE), however, have acquired an exogenous PBP (Pbp2a) that exhibits low binding affinity
to β-lactams, thus rendering such strains clinically resistant to nearly all β-lactams [5, 7, 8].
Staphylococcal drug resistance is further exacerbated by the pathogen’s propensity to form a
biofilm, in which many bacterial cells display a “persister”-like state of low metabolic activity
and which renders antibiotics inactive, such as β-lactams that target active metabolic processes
including growth and cell division [9, 10]. Biofilm formation also mediates antibiotic drug
resistance by providing a complex and extensive polysaccharide extracellular matrix that serves
as an effective physical barrier to antibiotic penetration into the cell [11–13].
Wall teichoic acid (WTA) is an anionic glycophosphate cell wall polymer in Gram-positive
bacteria that is present in roughly equal amounts to PG [14]. Interestingly, WTA has important
functional roles in both the tolerance of methicillin-resistant Staphylococci to β-lactams [15–
19] as well as in biofilm formation [20–24]. WTA is synthesized using the lipid carrier bacto-
prenyl phosphate and a sequential series of cytosolic-exposed plasma membrane associated
Tar (teichoic acid ribitol) enzymes, starting with TarO and TarA [19, 22, 25–27] (Fig 1). The
polymer is subsequently translocated across the plasma membrane by an ABC transporter
encoded by TarG and TarH [22, 28, 29] and ultimately cross-linked to the cell wall PG, upon
which the liberated bactoprenyl carrier is recycled (Fig 1) [22, 25, 30–32].
Interestingly, genetic studies in S. aureus and S. epidermidis reveal that whereas deletions of
early WTA biosynthetic enzymes are nonlethal, but cause diverse attenuated virulence pheno-
types [27, 33, 35, 36], deletions of later steps in WTA biosynthesis are not generally tolerated
and the enzymes are normally essential for growth [28, 37, 38]. This is referred to as an ‘essen-
tial gene paradox’, and may be explained either by 1) the accumulation of toxic WTA
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intermediates, or 2) sequestration of a non-recyclable pool of lipid carrier accumulating in late
stage WTA deletion mutants such that bactoprenyl phosphate is unavailable to support PG
biosynthesis (Fig 1) [19, 28, 37–40].
While WTA is dispensable for growth amongst Gram-positive bacteria [28, 35, 37, 38], it
buffers methicillin-resistant Staphylococci from the action of β-lactam antibiotics [16, 17, 18,
33, 41] by coordinating peptidoglycan cross-linking [42] and targeting the major autolysin Atl
[43]. Accordingly, genetic or chemical inhibition of Tar enzymes restores the susceptibility of
MRSA and MRSE to β-lactams. Inhibitors to early (non-essential) enzymes in WTA biosynthe-
sis are particularly appealing as non-bioactive adjuvants or combination agents that, paired
with β-lactams, provide a promising strategy to treat MRSA and MRSE infections [16, 17, 33,
40, 41, 44, 45]. A growing number of small molecules targeting Tar enzymes have also been
identified [16, 33, 34, 39, 41, 45, 46]. Perhaps best known is tunicamycin, a natural product
structurally related to UDP-N-acetylglucosamine (UDP-GlcNAc), which inhibits TarO, the
first enzyme in WTA biosynthesis [16, 47]. Tunicamycin demonstrates strong synergistic activ-
ity in combination with β-lactam antibiotics, presumably by depleting the buffering capacity
WTA provides in β-lactam resistance of MRSA and MRSE. A variety of additional WTA inhib-
itors have also been demonstrated to target TarG, the membrane-associated subunit of the
WTA transporter [33, 34, 40, 48].
WTA biosynthetic enzymes have been extensively characterized in S. aureus [19, 22, 25–27,
49, 50]. However, the identity and characterization of the 2-epimerase which interconverts
UDP-GlcNAc and UDP-N-acetylmannosamine (UDP-ManNAc), each a substrate of TarO
and TarA respectively (Fig 1), has remained largely restricted to Bacillus subtilis [51]. Two
Fig 1. WTA biosynthesis pathway.WTA is sequentially synthesized by a series of Tar enzymes on a bactoprenyl phosphate carrier on the inner leaflet of
the cell membrane and eventually transported to the outer leaflet where it is cross-linked to peptidoglycan. See inset for details. Non-essential early steps in
WTA biosynthesis are shown as green arrows, late stage conditionally essential steps are shown as purple arrows. Note, MnaA is highlighted by a dashed
bidirectional green arrow, highlighting its novel functional role as an epimerase that interconverts UDP-GlcNAc and UDP-ManNAc, thus providing substrates
for TarO and TarA, respectively. L638 is a Staphylococcal-specific TarG inhibitor [33]. Schematic has been adapted from [34].
doi:10.1371/journal.ppat.1005585.g001
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proteins, Cap5P and MnaA, share homology to the B. subtilus 2-epimerase [51] and have been
suggested to potentially perform this function in S. aureus [52]. Cap5P and MnaA are 59.6%
identical and 77.2% similar in their amino acid sequence, and each has been demonstrated to
complement the phenotype of an E. coli strain lacking a 2-epimerase [52]. In addition, S. aureus
Cap5P epimerizes ~10% of UDP-GlcNAc to UDP-ManNAc in vitro, which is comparable to
the conversion levels observed for the E. coli and B. subtilis homologs [51, 52]. Disruption of S.
aureus cap5P, however, did not yield an observable phenotype [52], implying that Cap5P and
MnaA may share redundant functions associated with capsule and/or WTA biogenesis.
Herein we demonstrate that MnaA functions as the previously uncharacterized 2-epimerase
that interconverts UDP-GlcNAc and UDP-ManNAc, thus providing the corresponding sub-
strates of TarO and TarA in both S. aureus and S. epidermidis. Genetic evidence is provided
demonstrating that MnaA is essential for WTA production and β-lactam resistance in MRSA
and MRSE. Likewise, MnaA loss of function (LOF) mutants display restored susceptibility to
β-lactam antibiotics in a mouse MRSA and MRSE thigh infection model. Whereas MnaA
serves as the sole WTA 2-epimerase in S. epidermidis, MnaA and Cap5P provide overlapping
roles in S. aureusWTA biosynthesis. We also demonstrate that MnaA is required for biofilm
formation by methicillin-resistant Staphylococci, thus contributing to dual mechanisms of β-
lactam resistance. We have determined the 1.9Å resolution crystal structure of S. aureusMnaA
protein and describe critical residues for enzymatic dimerization, stability, and substrate bind-
ing. Finally, we demonstrate that tunicamycin, a known non-competitive inhibitor of TarO,
also inhibits MnaA activity in vitro and discuss the potential therapeutic implications of WTA
2-epimerase inhibitors from the perspective of anti-Staphylococcal β-lactam combination
agents.
Results
MnaA identification and functional role in WTA biogenesis in vivo and in
vitro
Late steps of WTA biosynthesis are conditionally essential in S. aureus and S. epidermidis;
genetic deletion or chemical inhibition of late WTA biosynthesis enzymes abolishes growth
but can be tolerated provided early steps of WTA biosynthesis are also inactivated [28, 33, 37,
38, 40]. Accordingly, LOF mutations in early non-essential steps in WTA biosynthesis, such as
TarO and TarA, act as bypass suppressors of late stage WTA inhibitors [16, 33, 34, 41]. To
explore whether additional yet previously uncharacterized genes participate in early aspects of
WTA biosynthesis, we used the previously published TarG inhibitor, L638 [33], as a chemical
probe to screen for novel bypass suppressor mutations. Extensive L638-resistant (L638R)
mutant selections were performed in both MRSA COL and MRSE CLB26329 strains.
As expected, multiple independently derived missense mutations mapping either to tarG, or
LOF mutations mapping to tarO and tarA were identified in both strain backgrounds following
whole genome sequencing (WGS) as previously reported [33]. Interestingly, in S. epidermidis,
multiple (n = 9) independently derived L638R mutations specifically isolated in this subsequent
screen mapped tomnaA, encoding a putative UDP-GlcNAc:UDP-ManNAc 2-epimerase [52]
not previously implicated as a suppressor of defects in late stage WTA biosynthesis in Staphylo-
cocci (Fig 2A). As WGS analysis indicates that each resistor isolate contains no additional non-
synonymous mutations in their genome, we presumedmnaAmutations are causal for the
L638R phenotype observed. Unlike L638R tarGmutations which are exclusively missense
mutations conferring drug resistant amino acid substitutions to the target protein [33], L638R
mnaAmutations encompass nonsense, frameshift, and missense mutations (Fig 2A), therefore
implying drug resistance is likely achieved by LOF mutations that possibly impair WTA
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biosynthesis. Finally, as TarO and TarA, respectively, require UDP-GlcNAc and UDP-Man-
NAc as substrates for initiating WTA polymer synthesis and an ortholog of MnaA was
described to participate in B. subtilisWTA polymer synthesis [51] we investigated the func-
tional role of MnaA in methicillin-resistant Staphylococci.
To directly evaluate the consequence of thesemnaAmutations, WTA of the corresponding
mutants was extracted and polymer levels visualized on an alcian blue-silver stained SDS
Fig 2. Whole-genome sequencing of L638R mutants. Heat map summary of all non-synonymous mutations identified by Illumina-based whole-genome
sequencing (100X genome coverage) of L638R mutants in MRSE CLB26329 (A) or MRSA COL (B). Red, non-synonymous mutation; grey, no change versus
parental genome sequence; yellow, non-synonymous mutations in genes other thanmnaA. Genome position, base pair change, and resulting amino acid
residue substitution are highlighted. Note: with only one exception (Δcap5PmnaASa
D281Y), no additional non-synonymous mutations besides the indicated
mnaAmutation were identified in each of the drug resistant strains examined.
doi:10.1371/journal.ppat.1005585.g002
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PAGE gel (Fig 3A and S1 Fig). As predicted, all MRSEmnaAmutants are completely depleted
of WTA (Fig 3A and S1 Fig, right), mirroring tarOSe
G84 and tarASe
G129R LOF mutants (Fig 3A;
[33]). Importantly, like previously described MRSE tarO and tarA LOF mutants [33], allmnaA
mutants display restored susceptibility to diverse β-lactams, with their minimal inhibitory con-
centration (MIC) below the clinical breakpoint defined for resistance to these agents (Table 1
and Table A in S1 Text). MRSEmnaA LOF mutants are up to 1000-fold more sensitive to imi-
penem, 256- to 512-fold more sensitive to nafcillin and 512-fold more sensitive to dicloxacillin
compared to the parental MRSE strain (Table 1 and Table A in S1 Text). Notably, this dramatic
antibiotic sensitization is specific to β-lactams (Table A in S1 Text).
RepresentativemnaA and Δcap5Pmutations in MRSA and MRSE as well as complementa-
tion strains thereof are shown. Minimum inhibitory concentrations (MIC; μg ml-1) of β-lac-
tams imipenem (IPM), nafcillin (Naf), and dicloxacillin (Dic) are provided. L638 is included to
quantify drug resistance of bypass mutations.
Analogous L638R mutant selections performed in MRSA COL were unsuccessful in identi-
fyingmnaA LOF mutants. Unlike S. epidermidis, however, S. aureusmaintains a second
2-epimerase involved in serotype 5 capsular polysaccharide (CP5) synthesis, Cap5P (S2A Fig)
[52]. To determine whether L638R mnaA LOF mutants were not identified in MRSA COL due
to a functional redundancy between Cap5P and MnaA, a cap5P deletion mutant was con-
structed (S3 Fig) and the L638R studies were repeated. Under these conditions, in addition to
identifying the expected tarG L638R mutations as well as tarO and tarA LOF mutations, multi-
ple (n = 11) independent resistor isolates obtained uniquely possess distinct mutations that
map tomnaA and are predicted to inactivate gene function as well as directly confer L638R
drug resistance based on the absence of additional non-synonymous mutations in their
Fig 3. MnaA loss of function mutants in MRSA and MRSE fail to produceWTA.WTA extraction and SDS PAGE analysis from L638R MRSE CLB26329
(A) and MRSA COL (B) mutants. Note, wild-type MRSAWTA polymers appear as a ladder of discretely sized bands whereas a more diffuse staining of
MRSEWTA polymer is observed. WTAmaterial was normalized to cell biomass prior to loading. Wild-type copies of cap5P,mnaASa, andmnaASe, as well as
the empty vector introduced into these strains for complementation studies are indicated. The tarO and tarA deletion mutants serve as a control for complete
impairment of WTA polymer production.
doi:10.1371/journal.ppat.1005585.g003
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genome following WGS analysis (Fig 2B). While MRSA COL Δcap5P exhibits no WTA deple-
tion phenotype and remains resistant to β-lactams, MRSA COLmnaA, Δcap5P double mutants
are completely devoid of WTA and are also highly sensitive to β-lactams (Fig 3B and Table 1
and Table A in S1 Text), again mirroring the restored β-lactam susceptibility of tarO and tarA
deletion mutants [16, 33, 41]. Indeed, MRSA COLmnaA Δcap5P double mutants are 32- to
64-fold more sensitive to imipenem, 8- to 16-fold more sensitive to nafcillin, and 16- to 32-fold
more sensitive to dicloxacillin compared to either Δcap5P or the isogenic parental strain
(Table 1 and Table A in S1 Text).
Consistent with the functional role of MnaA in WTA biogenesis, MRSA COLmnaA, cap5P
double mutants and MRSE CLB26329mnaA single mutants display related growth and mor-
phological defects as observed for S. aureus ΔtarO and ΔtarAmutants. For example, in both
MRSA and MRSE strains examined, genetic inactivation of MnaA /Cap5P function led to a
slightly reduced growth rate within the first 6 h of growth in fresh medium but no apparent dif-
ference in cell density versus the wild-type control over a 24 h extended growth period (S4 Fig).
Similarly, super resolution microscopy analysis of MRSA COLmnaA, cap5P double mutants
and MRSEmnaA single mutants revealed morphological phenotypes consistent with WTA
depletion [16], including increased cell size heterogeneity and septation defects (S5 and S6
Figs).
Genetic complementation studies further demonstrate the overlapping functional activity of
MnaA and Cap5P in Staphylococci. Complementing Δcap5P mnaASa
P12L and Δcap5P
mnaASa
Y194 with either cap5P ormnaASa reintroduced on an inducible plasmid restored
WTA polymer levels, resistance to each of the β-lactams tested, and wild-type sensitivity to
L638 (Fig 3B and Table 1). Interestingly, cross complementation of these mutants withmnaASe
Table 1. Genetic inactivation ofmnaA in methicillin-resistant Staphylococci restores β-lactam
susceptibility.
MIC (μg ml-1)
Strain IPM Naf Dic L638
MRSA COL 32 > 64 > 64 2
Δcap5P 32 > 64 > 64 2
Δcap5P mnaASa
P12L 1 8 4 16
Δcap5P mnaASa
P12L/mnaASa 8 32 32 2
Δcap5P mnaASa
P12L/cap5PSa 8 32 32 2
Δcap5P mnaASa
P12L/mnaASe 0.25 16 4 2
Δcap5P mnaASa
Y194* 1 8 2 16
Δcap5P mnaASa
Y194*/mnaASa 16 32 64 2
Δcap5P mnaASa
Y194*/cap5PSa 16 32 64 2
Δcap5P mnaASa
Y194*/mnaASe 4 16 16 2
MRSE CLB26329 64 > 64 > 64 4
mnaASe
ΔY151 0.25 0.25 0.125 16
mnaASe
ΔY151/mnaASa > 64 64 > 64 8
mnaASe
ΔY151/cap5P > 64 32 > 64 8
mnaASe
ΔY151/mnaASe > 64 32 > 64 8
mnaASe
G171D 0.25 0.125 0.125 16
mnaASe
G171D/mnaASa > 64 32 > 64 8
mnaASe
G171D/cap5P > 64 64 > 64 8
mnaASe
G171D/mnaASe > 64 64 > 64 8
doi:10.1371/journal.ppat.1005585.t001
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also restored WTA production, albeit only partially restored wild-type drug susceptibilities
(Fig 3B and Table 1). Similarly,mnaASe
Δ151 andmnaASe
G171D were also fully complemented
for each of the above phenotypes by reintroducing a wild-type plasmid-based copy ofmnaASe
(Fig 3A and Table 1). Strikingly, introduction of eithermnaASa or cap5P fully restored WTA
production, β-lactam resistance, and L638 susceptibility ofmnaASe LOF mutants (Fig 3A and
Table 1). To further investigate β-lactam susceptibility phenotypes associated withmnaA inac-
tivation, kill curve experiments were performed against MRSA and MRSE strains treated with
the β-lactam imipenem. Whereas imipenem (4 μg ml-1) is ineffective in inhibiting growth of
wild-type methicillin-resistant Staphylococci, imipenem displayed a dramatically restored bac-
tericidal activity against MRSA Δcap5P mnaASa
P12L as well as MRSEmnaASe
Δ151 strains, lead-
ing to a 3 log reduction in viable cells within 7 hr of drug treatment (S7 Fig). Similar to other
phenotypes examined, full complementation as well as heterologous complementation between
mnaA orthologs were again observed (S7 Fig). Collectively, these data demonstrate that
whereas MnaA seems to be one of two redundant UDP-GlcNAc:UDP-ManNAc 2-epimerases
in MRSA COL, it is the sole 2-epimerase required for WTA biosynthesis in MRSE CLB26329.
To evaluate the significance of the observed in vitro hypersensitivity ofmnaA, cap5P double
mutants to β-lactam antibiotics in an in vivo context, MRSA COL Δcap5P mnaASa
P12L, Δcap5P
mnaASa
Y194, and Δcap5P mnaASa
D281Y strains were used to conduct imipenem efficacy studies
in a previously described murine deep thigh model of infection [53]. Imipenem is ineffective at
treating animals infected with wild-type MRSA COL or the Δcap5Pmutant when dosed three
times daily (TID) with 10 mg kg-1 imipenem over 24 hours (Fig 4A) [33]. Conversely, imipe-
nem efficacy is significantly restored against MRSA in Δcap5P mnaASa
P12L, Δcap5P
mnaASa
Y194, and Δcap5P mnaASa
D281Y mutants, ranging between a 2–3 log reduction of bacte-
rial burden versus control strains after imipenem treatment (Fig 4A). As MRSE displays some-
what greater sensitivity to imipenem in our infection model, a lower dose (2.5 mg kg-1) was
required to demonstrate restored efficacy of imipenem against themnaASe mutant. Here again,
mice administered imipenem (TID) at this non-efficacious dose and infected with themnaASe
mutant possessed a significantly reduced (> 3 log) bacterial burden versus the wild-type MRSE
parent, similar to the effects of tarOSe
G84 and tarASe
G129R mutants (Fig 4B).
MnaA-mediatedWTA biosynthesis is required for biofilm formation
Since deletion of tarO has been shown to be important for biofilm formation and attachment
[20–24], we evaluated the role ofmnaA, cap5P, and other WTA biosynthesis genes in this pro-
cess. MRSA COL strains with LOF in early (tarA, tarO) and intermediate (tarB, tarD, tarI’)
steps in WTA biosynthesis [33] were all substantially defective in biofilm formation (Fig 5A).
Conversely, Δpbp3 and Δpbp4 single mutants as well as the Δpbp3 Δpbp4 double mutant con-
trol strains faithfully produced biofilms indistinguishable from the wild-type MRSA COL par-
ent (Fig 5A). MRSE strains deleted of tarOSe
G84 or tarASe
G129R also failed to form robust
biofilms (Fig 5B). Paralleling this WTA-mediated role in biofilm formation and attachment,
mnaASe mutants and Δcap5P mnaASamutants similarly displayed impaired biofilm formation.
MRSA COL Δcap5Pmutants, however, failed to impair biofilm formation (Fig 5A), consistent
with its lack of phenotypes related to WTA biogenesis, β-lactam susceptibility, and virulence.
Fluorescence microscopy on stained, similarly grown, and treated biofilms confirmed these
phenotypes (Fig 5C and 5D and S8 and S9 Figs). Genetic complementation of the biofilm
impairment observed in Δcap5P mnaASa
P12L and Δcap5P mnaASa
Y194 is fully achieved by rein-
troducing either wild-type S. aureus gene and partially achieved by S. epidermidis mnaA (Fig
5A and 5C and S8 Fig). Similarly, impaired biofilm formation ofmnaASe
ΔY151 was faithfully
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complemented by reintroduction ofmnaA as well as S. aureus mnaA or cap5P (Fig 5B and 5D
and S9 Fig), again reiterating a strong functional overlap between these 2-epimerases.
To test whether known inhibitors of WTA biogenesis similarly disrupt biofilm formation,
MRSA and MRSE strains were grown as above and treated with sub-MIC concentrations of
tunicamycin or L638. Tunicamycin treatment at levels shown to completely inhibit WTA pro-
duction [17, 35] decreased biofilm formation to amounts similar to those achieved by genetic
inactivation of its target, TarO (Fig 5B, 5C and 5E and S8 and S9 Figs). Similarly, L638 treat-
ment at sub-MIC levels that do not dramatically affect growth produce a dose-dependent inhi-
bition of biofilm formation (Fig 5A, 5B and 5C and S8 and S9 Figs). Conversely, neither
tunicamycin nor L638 similarly tested singly or in combination with a sub-MIC level of imipe-
nem significantly disrupted the gross morphology, adherence, viability or antibiotic suscepti-
bility of pre-existing biofilms (S10 Fig). Therefore, inhibition of WTA synthesis can prevent
the establishment of a biofilm growth state, presumably by disrupting the early attachment
step in biofilm colonization, but does not significantly impair biofilm viability or disrupt the
extracellular matrix of pre-existing biofilms.
Lipoteichoic acid (LTA), another cell surface teichoic acid common to Gram-positive bacte-
ria, has also been reported to play a role in biofilm formation [54, 55] and co-depletion of
WTA and LTA demonstrate a synthetic lethal genetic interaction in both B. subtilis [56] and S.
Fig 4. MRSA andMRSEMnaA LOFmutants are highly susceptible to imipenem in a murine thigh infection. Immune-suppressed CD-1 mice (5 per
group) were challenged intramuscularly with the parental MRSA COL strain, MRSA Δcap5P, or MRSA Δcap5PmnaASa LOFmutants (A) or with the parental
MRSE strain versusmnaASe, tarOSe and tarASe LOF mutants (B) and treated three times daily (TID) with imipenem (IPM). Thighs were harvested at 24hrs,
homogenized and plated to determine CFU per thigh. (A) Restored efficacy of IPM (10 mg kg-1) against MRSA Δcap5PmnaASa
P12L, Δcap5PmnaASa
Y194*,
and Δcap5PmnaASa
D281Y. Following IPM treatment, bacterial burden amongst mice infected with Δcap5PmnaASa
P12L, Δcap5PmnaASa
Y194*, and Δcap5P
mnaASa
D281Y is reduced approximately 2–3 log at 24 hrs versus those infected with MRSA COL or Δcap5P controls. * p<0.01 versus parent at 24 hr; $
p<0.05 versus respective 24 hr vehicle. (B) Restored efficacy of IPM (2.5 mg kg-1) against MRSEmnaA, tarO, and tarA LOFmutants. Reduction in bacterial
burden of mice infected with themnaASe
G171D is comparable to those infected with tarOSe
G84* or tarASe
G129Rmutants, yielding an approximate 3 log
reduction in 24 hr IPM treatment versus the wild-type control. Note, as MRSE CLB26329 is more susceptible to IPM than MRSA COL, its dose was reduced
to 4-fold versus the MRSA efficacy study (A).
doi:10.1371/journal.ppat.1005585.g004
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Fig 5. WTA is required for biofilm formation in methicillin resistant Staphylococci. For total biofilm quantification, biofilms were grown in triplicates for
24 hours in 96-well plates with or without indicated sub-MIC concentrations of WTA inhibitors for MRSA COL (A,C,E) and MRSE CLB26329 (B,D) strains.
Genetic complementation of described mutants was performed using plasmid-based copies of wild-type cap5P (pcap5P),mnaASa (pmnaASa), andmnaASe
(pmnaASe) as indicated. Biofilms were stained with safranin and dissolved in glacial acetic acid before OD564 was measured. Bars represent mean OD, error
bars represent standard deviation. For Epi fluorescence microscopy, biofilms of MRSA (C) and MRSE (D) were grown as above in black clear bottom plates
and stained with BacLight Green fluorescent stain. Z-stacks were obtained at 60x magnification. Scale bar = 10 μm.
doi:10.1371/journal.ppat.1005585.g005
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aureus [57]. Accordingly, we tested whether depletion of both WTA and LTA synergistically
impair biofilm formation. Since LTA is essential [58], a previously described partial LOF ltaSSa
mutant that produces lower levels of LTA than the parental strain [59] was tested for biofilm
formation both in the absence and presence of increasing tunicamycin concentrations.
Whereas the ltaS defective strain exhibits a slight 2-fold reduction in biofilm formation, treat-
ment with sub-MIC levels of tunicamycin produces a dose dependent further reduction in bio-
film formation approaching that of tarSamutants (Fig 5E). Interestingly, this baseline level of
residual biofilm formation in the ltaSSa mutant background was achieved with ~10 percent the
normal concentration of tunicamcyin required to similarly impair biofilm in the wild-type par-
ent strain (Fig 5E). Such an apparent synergistic effect further suggests a functional interdepen-
dence between these teichoic acid biosynthetic pathways and biofilm formation.
MnaA crystal structure and binding to tunicamycin
The MRSA COLMnaA crystal structure was solved at 1.9Å resolution (Fig 6A). The protein
crystallizes with a dimer in the asymmetric unit. The structure is closely related to that of other
bacterial 2-epimerases (root-mean-square (RMS) deviation differences with E. coliMnaA in
Cα positions for all atoms in a monomer between 1.40 and 2.90Å depending on the chains
being compared), and a similar dimerization interface and quaternary structure is observed
(Fig 6B). While there are significant structural differences between the E. coli and S. aureus
models, they are located on the protein surface, away from either the substrate binding site or
the oligomerization interface. Surprisingly, there are differences between the two monomers in
the S. aureusMnaA structure: the RMS. deviation in positions for all Cα is about 1.0Å. We
refer in the following the structure of the ternary complex between MnaA, UDP and UDP-Glc-
NAc as the “closed” form [60], and other states of the protein, either in apo form or a binary
complex with UDP, as the “opened” form, consistent with past structural characterization of
the enzymes [60]. This difference between monomers is comparable to the differences with the
structure of the E. coli enzyme (PDB entry 1F6D) in opened form, 1.0 to 1.9Å, depending on
which chains are compared. However, further comparisons show that the differences with the
closed form are less when comparing to one of the monomers in the S. aureus crystal structure
rather than the other (RMS deviation of 1.2Å for 354 atoms in the superposition with B.
anthracisMnaA in complex with UDP and UDP-GlcNAc (closed form), PDB entry 3BOV,
versus 1.4Å for 340 atoms for the other monomer (See also Fig 6)). In addition to differences in
the quaternary structure, other significant local structural rearrangements distinguish the two
monomers. Notably, His 205 to Gly 211 (E. coliHis 213 to Gly 219, B. anthracisHis 209 to Gly
215) differ significantly, but in the monomer nearer to the closed form adopts a conformer
similar to the one observed in the closed form [61]. By contrast, the same loop in the other
monomer has a local fold similar to the one found in theM. jannaschii epimerase in apo form
(PDB entry 3NEQ). Collectively, crystallographic results described here allow for a more
refined understanding of the enzyme regulation at a structural level: a dynamic equilibrium
between the opened form and an “intermediate closed” conformer of the enzyme is present in
solution in apo form or in presence of UDP only. The equilibrium is moved and locked
towards the “closed” form in the ternary complex with UDP—UDP-GlcNAc.
L638R bypass mutants corresponding to MnaA LOF mutants were mapped to the MRSA
COLMnaA crystal structure (Fig 6C and 6D). Among eight MnaA LOF mutations isolated in
MRSE (Fig 2A), only the Gly283/Arg and Pro131/Leu mutations are located at the ligand
(UDP and UDP-GlcNAc) binding sites. Gly283/Arg is positioned at an area across both the
UDP and UDP-GlcNAc binding sites (UDP-GlcNAc binding site was mapped from the struc-
ture of UDP-GlcNAc bound Bacillus anthracis 2-epimerase (PDB ID 3BEO) through structure
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Fig 6. Mapping of MnaA LOFmutations into the MnaA crystal structure reveal key residues for substrate binding site stability and charge. (A)
Overall MRSA COLMnaA crystal structure. The molecular surface is shown in grey. The protein is represented as a cartoon. In all figures one monomer is
consistently colored in orange and the other in cyan, and the bound UDPmolecules are shown as sticks, methyl groups colored in light blue. Nitrogen,
oxygen and phosphor atoms are in blue, red or orange, respectively. (B,C,D,E) Comparison with theM. jannaschii structure in “opened” form (PDB 3NEQ) or
“closed” form (PDB 3NES). Both structures are represented as ribbons, one monomer at a time, and UDP as sticks. (B) and (C) compares the opened form,
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overlay) as shown in the X-ray structure of MnaA (Fig 6B). The large side-chain of Arg residue
may cause van der Waals (VDW) clashes with the ligands and surrounding residues, thus
interfere with binding of substrate UDP-GlcNAc and intermediate UDP, and destabilize the
protein. The Pro131/Leu mutation is adjacent to the UDP-GlcNAc binding site and close to
the dimer interface; it could both affect substrate binding and dimer stability through VDW
conflicts by the Leu side-chain. Mutations Pro129/Thr, Gly171/Asp, Asp281/Glu and Arg300/
Ile introduce amino acids with bulkier side-chains, compromise the favorable hydrogen bonds
and hydrophobic interactions around the wild-type residues, and thus decrease protein stabil-
ity. Protein stability could also be dramatically reduced by the deletion at Lys151 and the inser-
tion at His76, the latter of which is located right in the middle of a helix, which is packed
against the other monomer at the dimer interface. Mapping of MnaA LOF mutations isolated
in MRSA COL Δcap5P (Fig 2B) into the S. aureusMnaA structure shows that all the sequence
changes are in close proximity to the substrate binding site or the UDP-GlcNAc binding site
(Fig 6D), therefore rendering the enzyme inactive.
Tunicamycin targets multiple UDP-GlcNAc binding enzymes. At higher drug concentra-
tions tunicamycin binds MraY, a UDP-N-acetylmuramoyl-pentapeptide: undecaprenyl-phos-
phate phospho-N-acetylmuramoyl-pentapeptide transferase enzyme involved in
peptidoglycan synthesis [62]. However, at low drug concentrations, tunicamycin selectively
inhibits TarO [34, 47]. Considering MnaA and Cap5P are epimerases responsible for intercon-
verting UDP-GlcNAc and UDP-ManNAc and that TarO utilizes the same substrate, we tested
whether tunicamycin may also bind MnaA and Cap5P. To test this possibility, we performed
saturation transfer difference (STD) nuclear magnetic resonance (NMR) studies, which allow
for the detection of transient binding of small molecules to proteins [63]. Such studies using
15 μM tunicamycin in the presence or absence of 5 μM of S. aureusMnaA or Cap5P protein
revealed binding of tunicamycin to both MnaA and Cap5P, as evidenced by the tunicamycin
specific peaks appearing only when run in the presence of 2-epimerases (Fig 7A, 7C, 7D and
7F).
Tunicamycin inhibits MnaA enzymatic activity
Binding of tunicamycin indicated that MnaA may represent an additional target of the nucleo-
side antibiotic in WTA biosynthesis beyond TarO. Functional reconstitution of the MnaA-cat-
alyzed reaction in vitro followed by capillary electrophoresis (CE) analysis with UV detection
showed the interconversion of UDP-GlcNAc and UDP-ManNAc, confirming 2-epimerase
activity (S11 Fig). Enzyme kinetics (Michaelis-Menten constant, Km, and maximal velocity,
Vmax) were determined for both, forward and reverse reaction. The conversion of UDP-Glc-
NAc to UDP-ManNAc (forward reaction) was in the linear range (steady-state phase) for up to
75 min (S12A Fig), while the reverse reaction exhibited a lag-period of 50 min after reaction
initiation and reached equilibrium after 180 min (S12B Fig). MnaA displayed a Km value of
411 ± 57 μM for UDP-GlcNAc and a Vmax value of 0.171 ± 0.037 μmol/min/mg protein. A Km
value of 131 ± 21 μM for UDP-ManNAc and a Vmax value of 0.159 ± 0.021 μmol/min/mg
in grey, with each monomer, while the superposition is with the closed form, in (D) and (E), drawn in purple. The RMS deviation in Cα positions are 1.6Å for
262 atoms, 1.6Å for 256 atoms, 1.5Å for 321 atoms, and 1.3Å for 336 atoms, for the superpositions in cartoon (B), (C), (D) and (E), respectively. (F) Mapping
MRSE LOF mutants. Eight mutation sites are mapped onto the X-ray crystal structure of UDP bound MRSA COLMnaA. The allosteric site ligand
UDP-GlcNAc was taken from the structure of UDP-GlcNAc bound B. anthracis 2-epimerase (PDB ID 3BEO). UDP and UDP-GlcNAc are displayed as thin
lines with the carbon atoms colored in light blue. One monomer of MnaA dimer is colored in cyan and the other in white. The mutation sites are highlighted in
stick. The carbon atoms of the wild-type residues are colored in yellow; those of the mutant residues are in green. (G) Mapping MRSAmnaA LOFmutants.
LOFmutations isolated in MRSA COL MnaA are highlighted. All coloring as in (C), but for simplicity, only the original sequence is shown.
doi:10.1371/journal.ppat.1005585.g006
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protein were determined for the reverse reaction (S12B Fig). The reversible reaction attained
an equilibrium ratio of 9:1 in favor of UDP-GlcNAc, in line with reported epimerization ratios
ranging from 12:1 to 9:1 for homologous enzymes [52, 64,] including the orthologous MnaA
2-epimerase required for B. subtilisWTA biosynthesis [51]. Testing tunicamycin in the in vitro
system revealed a dose-dependent inhibition of MnaA (Fig 8), verifying that the 2-epimerase
indeed represents a secondary target within the WTA biosynthesis pathway.
Discussion
Here, we describe genetic, biochemical, and X-ray crystal structure studies revealing the func-
tional role of MnaA and Cap5P, encoding 2-epimerases which interconvert UDP-GlcNAc and
UDP-ManNAc and provide the requisite substrate for the two first enzymes involved in Staph-
ylococcal WTA biosynthesis, TarO and TarA, respectively. Whereas most of the enzymes
involved in WTA polymer synthesis have been extensively characterized, the role of 2-epimer-
ases in this process has remained largely enigmatic amongst medically relevant Staphylococci.
Presumably, this is due to the genetic redundancy between MnaA and Cap5P in S. aureus and
the limited studies of WTA biogenesis performed in S. epidermidis, where its identification is
uniquely amenable by genetic means. To identify the functional contribution of MnaA in
Staphylococcal WTA biosynthesis, L638, a recently discovered WTA inhibitor with potent S.
Fig 7. Biophysical studies demonstrate MnaA and Cap5P bind tunicamycin. (A, D) 600 MHz 1H NMR spectra of 15 μM tunicamycin. (B, E) 1H NMR
STD spectra of 15 μM tunicamycin without 2-epimerase. (C) 1H NMR STD spectra of 15 μM tunicamycin in presence of 5 μMMnaA. (F) 1H NMR STD
spectra of 15 μM tunicamycin in presence of 5 μMCap5P. Saturation of the protein was achieved with a Gaussian pulse cascade resulting in a total
saturation time of 3s. The protein resonances were saturated at 100 Hz and the off resonance was set to -120 ppm. Tunicamycin-specific peaks in NMR STD
spectra were only obtained in the presence of MnaA or Cap5P. (G) Structure of tunicamycin.
doi:10.1371/journal.ppat.1005585.g007
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epidermidis activity was used as a chemical probe to screen for novel bypass suppressor muta-
tions able to reverse the drug’s bacteriostatic effect [33]. Extensive genetic and chemical biology
evidence predict that in addition to target-based drug resistant mutations, additional bypass
mutations may arise and reflect gene inactivation mutations in early non-essential steps in
WTA biosynthesis [33, 34]. Accordingly, bypass mutations in tarO and tarA as well asmnaA
were uncovered by L638R suppressor analysis and WGS of resistor isolates. Indeed, an exten-
sive characterization ofmnaA and cap5Pmutant phenotypes in both MRSA and MRSE
described here reveal that WTA 2-epimerases serve as a new and highly unconventional class
of antibiotic drug targets.
Unlike traditional antibiotic drug targets, MnaA and other early stage WTA enzymes are
not essential for cell growth or viability. In fact, genetic inactivation of MnaA 2-epimerase
activity resulted in only a minimal effect on Staphylococcal growth rate. However,mnaA
mutant phenotypes faithfully recapitulate those of tarO and tarAmutants and reveal multiple
therapeutic contexts in which a cognate inhibitor to MnaA could provide broad efficacy against
methicillin-resistant Staphylococci. Firstly, we demonstrate these 2-epimerases are essential for
WTA synthesis in both MRSA and MRSE and depletion of WTA dramatically restores β-lac-
tam susceptibility to these drug resistant pathogens both in vitro as well as in relevant mouse
infection models. Therefore, as we and others have proposed [8, 16, 17, 33, 45, 65–67], inhibi-
tors to such β-lactam potentiation targets could serve as novel adjuvants to partner with exist-
ing β-lactams to restore bactericidal therapeutic activity against β-lactam resistant
Staphylococci. We also provide extensive evidence that abolishing WTA biosynthesis renders
methicillin-resistant Staphylococci unable to effectively form robust biofilms. Accordingly,
inhibitors of early stage WTA biosynthetic enzymes, including MnaA, may also serve as pro-
phylactic agents to prevent Staphylococcal biofilm formation. As inhibitors of any of these tar-
gets are not expected to display antibacterial activity, such prophylactic agents are also
predicted to be highly selective and spare the gut microbiota from antibiotic-mediated alter-
ations. Finally, as ΔtarO strains exhibit dramatically attenuated virulence phenotypes across
Fig 8. Tunicamycin inhibits MnaA in a concentration-dependent manner.Representative
electropherograms of the MnaA-catalyzed conversion of UDP-ManNAc to UDP-GlcNAc in the absence of
tunicamycin (A), in the presence of 100 μM (B) and 200 μM tunicamycin (C). Substrate concentration is
100 μM. Peaks: 1 UDP-ManNAc; 2UDP-GlcNAc.
doi:10.1371/journal.ppat.1005585.g008
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diverse animal infection models tested [35, 55, 68], WTA 2-epimerase inhibitors may also pro-
vide prophylactic or therapeutic utility as novel anti-virulence agents.
Surprisingly, S. epidermidis encodes only a single epimerase whereas S. aureus encodes two
related enzymes amongst all published genomes we have examined. This likely reflects that S.
aureus expresses a second epimerase involved in capsular biosynthesis, which is not produced
by S. epidermidis. Indeed, S. aureus Cap5P epimerizes UDP-GlcNAc and UDP-ManNAc and
participates in CP5 synthesis [52, 69]. Therefore, whereas S. epidermidisMnaA appears solely
responsible for WTA synthesis, S. aureus requires a second enzyme to fulfill the biosynthetic
needs of two disparate cell wall polymers. Interestingly, B. anthracis also requires two highly
related 2-epimerases to fulfill biogenesis of the S-Layer, a cell wall elaboration analogous to
WTA in many ways, and one member (GneZ) is essential for vegetative growth [70].
Biochemical analysis of MnaA revealed that the 2-epimerase interconverts UDP-GlcNAc
and UDP-ManNAc, demonstrating reversible epimerase activity. At equilibrium the conver-
sion of UDP-GlcNAc to UDP-ManNAc attained ~10%, thereby limiting the available amount
of UDP-ManNAc for WTA biosynthesis. This agrees well with the required prioritization of
UDP-GlcNAc for the essential processes of peptidoglycan biosynthesis within the cell. MnaA
may thus resemble a checkpoint that contributes to control the flux of UDP-GlcNAc and chan-
nel the shared soluble cell wall precursor into the different synthesis pathways.
As TarO, MnaA and Cap5P all bind a common substrate, UDP-GlcNAc, we examined
whether the 2-epimerases potentially serve as additional WTA targets of tunicamycin. Tunica-
mycin is a natural product-derived antibiotic that is structurally related to UDP-GlcNAc and
can bind in the active sites of TarO [47] and MraY [16, 62]. We demonstrate that tunicamycin
also binds to purified MnaA and Cap5P by STD NMR and inhibits the MnaA catalyzed inter-
conversion of UDP-GlcNAc and UDP-ManNAc in a dose-dependent fashion in vitro. These
findings may explain the tremendous potency of tunicamycin as a WTA inhibitor versus a PG
inhibitor. Whereas tunicamycin displays a relatively low activity against S. aureus
(MIC = 32 μg ml-1), it is a highly potent WTA inhibitor (IC50 = 50 ng ml
-1) [16]. We speculate
this preferential inhibitory activity of WTA over PG biosynthesis may in part reflect that tuni-
camycin inhibits both TarO and MnaA/Cap5P-mediated steps in WTA biosynthesis and that
even partial inhibition of each enzyme in the pathway may be synergistic in a whole cell con-
text, analogous to the synergistic mechanism of combining trimethoprim (TMP) and sulfon-
amide (SULF) antibiotics [5]. Unlike the chemical synergy achieved by TMP and SULF,
however, tunicamycin may achieve this effect due to its polypharmacological effects as a single
agent. Notably, a single agent antibiotic with multiple targets is predicted to possess a very low
propensity for drug resistance, which is true for tunicamycin. Therefore, a non-toxic analog of
tunicamycin, alternative active site inhibitor, or allosteric inhibitor of TarO and MnaA/Cap5P
may all benefit by displaying potent WTA inhibitory activity as well as an extremely low fre-
quency of resistance. Finally, due to the limited homology between MnaA and the closest
human BLASTP homolog, GNE2 (S2B Fig), it is unlikely that host 2-epimerases would be
affected.
Based on the crystal structure of the B. anthracis UDP-GlcNAc 2-epimerase, an in silico
screen was recently performed to identify a UDP-GlcNAc 2-epimerase inhibitor named epi-
merox [71, 72]. Although several chemotypes of epimerox are reported to recapitulate terminal
phenotypes of the B. anthracis epimerase conditional mutant, no direct genetic, biochemical,
biophysical, or structural data are provided to independently reinforce this conclusion. Surpris-
ingly, epimerox displays potent S. aureus activity (MIC = 8 μg ml-1) [71] and S. epidermidis
activity (MIC = 2 μM) [72] despite our conclusion that 2-epimerase activity is dispensable for
growth in MRSA COL, MRSE CLB26329, and the routinely studied methicillin-sensitive S.
aureus strain, RN4220 (S13 Fig). Such a paradox between the bioactivity of epimerox and non-
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essentiality of its reported drug target in multiple different strain backgrounds suggest that
additional mechanism of action studies seem warranted, including whether epimerox effec-
tively inhibits WTA synthesis, synergizes in combination with β-lactams, and/or prevents bio-
film formation or Staphylococcal virulence. Determining the S. aureusMnaA crystal structure
as well as key residues essential for enzyme function offers important new resources to assist
MnaA inhibitor discovery.
Methods
Strains, media, chemicals, growth conditions
MRSA COL is a hospital-acquired penicillinase-negative strain extensively used in Staphylococ-
cus aureusmethicillin resistance and virulence studies [73, 74] and from which its genome has
been fully sequenced and annotated [75]. MRSE strain (MB6255) is a previously described
methicillin-resistant S. epidermidis clinical isolate (CLB26329; [76]) isolated from a New York
ICU in 2004. All strains were grown in trypticase soy broth (TSB) or cation-adjusted Mueller
Hinton broth (CAMHB) (Difco, BD, Franklin Lakes, New Jersey, USA) at 37°C, 250rpm unless
otherwise indicated. All compounds were prepared in DMSO. All strains are described in
Table C in S1 Text. All subcloning methods are described in S1 Text.
Isolation and genetic confirmation of LOF mutants
Approximately 1 x 109 cells of strains MRSE CLB26329, MRSA COL or Δcap5P grown to sta-
tionary phase overnight were spread on CAMHA (Difco) containing 16 μg ml-1 L638 for
MRSE (4-fold MIC) and 8 μg ml-1 L638 (4-fold MIC) for MRSA and Δcap5P. Plates were incu-
bated for 48–96 hours for MRSE and 48–72 hours for MRSA and Δcap5P. L638 resistance was
confirmed in a second round of growth on 16 μg ml-1 L638, and colonies were counter screened
against 8 μg ml-1 imipenem to differentiate mutations in TarG versus early and intermediate
steps in WTA biosynthesis. Genomic DNA was prepared from imipenem sensitive mutants
(DNEasy Blood & Tissue Kit, Qiagen, Venlo, Netherlands) and Sanger sequencing formnaA
was performed usingmnaA-locus specific primers 1731, 1732, 1733 and 1734 for MRSE and
primers 1525 and 1526 for MRSA (Table B in S1 Text). Sequence analysis was performed using
Sequencher 5.0 software. MnaA LOF mutations were independently confirmed by Illumina-
based whole genome sequencing (>100× genome coverage) (BGI Hong Kong). No additional
non-synonymous mutations were found in MRSE. Only one MRSA COL LOF mutant carried
an additional non-synonymous mutation (Fig 2).
Susceptibility testing
MICs were determined by the broth microdilution method in accordance with the recommen-
dations of the Clinical and Laboratory Standards Institute in 96 well plates and assayed visually.
MRSA strains were tested in CAMHB (Difco). MRSE strains were tested in Luria Bertani broth
(Difco).
WTA extraction andWTA-PAGE
Previously published [26]. Very briefly, stationary phase cells were used for extractions. Cells
were washed and boiled for one hour, and pellets harvested for further processing. WTA was
hydrolyzed and run on polyacrylamide gel electrophoresis.
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Mouse deep thigh model
Performed as previously published [53]. Briefly, immune-suppressed CD-1 mice (5 per group)
were challenged intramuscularly in the right thigh with 1x106 CFUs of MRSA for imipenem
efficacy or with indicated 10-fold dilutions for virulence studies. Mice were challenged with
2x106 CFUs of MRSE. For efficacy studies, mice were treated with indicated amounts of imipe-
nem (IPM). Thighs were harvested at 24hrs, homogenized and plated to determine CFU per
thigh.
Ethics statement
All animal procedures were performed in accordance with the highest standards for the
humane handling, care and treatment of research animals and were approved by the Merck
Institutional Animal Care and Use Committee. The care and use of research animals at Merck
meet or exceed all applicable regulations of the Animal Welfare Act as put forth by the United
States Department of Agriculture. The protocol number is 2018-300643-Jan. It was approved
in January of 2015 and will expire in January of 2018.
Biofilm assays
For total biofilm formation assays, wild-type MRSA COL or MRSE CLB26329 and their
derived loss of function mutants or MRSA COL ltaS hypomorph were grown in TSB (Difco)
with or without sub-MIC concentrations of drugs overnight at 37°C, 250rpm. Cultures were
normalized to OD600 = 1.5 and diluted 1/50 in TSB + 0.2% glucose with or without indicated
sub-MIC concentrations of drug. 200μl of culture were seeded in triplicate wells in duplicate
96-well plates pretreated overnight with bovine plasma (Lampire, Pipersville, Pennsylvania,
USA). Plates were incubated wrapped in parafilm at 37°C for 24 hours. One plate was shaken
to resuspend biofilm and pellicles in liquid and OD600 taken to quantify total growth per well.
The duplicate plate was processed for biofilm analysis. Supernatant was aspirated and wells
washed gently three times with H2O. Biofilms were then fixed with Bouin’s fixative (Electron
Microscopy Sciences, Hatfield, Texas, USA) for 15 minutes, supernatant removed and biofilms
stained with 0.1% safranin (Ricca Chemical Company, Arlington, Texas) solution for 15 min-
utes. Plates were washed under running tap water to remove excess stain. Stained biofilms were
dissolved in glacial acetic acid and OD564 measurements taken to quantify biofilm formation.
Readings were normalized to corresponding total growth readings from the duplicate plate.
For biofilm killing assays, biofilms were grown for 24 hours as above in the absence of com-
pounds before addition of compounds at indicated drug concentrations. Biofilms were incu-
bated another 24 hours, washed, fixed and stained with Syto 10 (Life Technologies, Carlsbad,
California, USA) for total cell staining and DEAD Red (Life Technologies) for membrane-
damaged, dead cell staining. Plates were excited at 492nm and emissions read at 505 and
615nm, respectively.
For fluorescence microscopy, biofilms were grown for 24 hours as above in Cellcoat black
μClear 96 well plates (Greiner Bio-one, Monroe, North Carolina, USA) in the absence or pres-
ence of compounds, supernatant was aspirated and wells washed gently three times with H2O.
Biofilms were then stained with 0.1 μM BacLight Green bacterial stain (Life Technologies) in
DPBS for 15 minutes, washed once and fixed with 4% formaldehyde for 30 minutes. Biofilms
were examined at 60x magnification on a Nikon Eclipse Ti using a FITC filter. Z-stacks were
acquired using NIS Elements AR software (Nikon, Tokyo, Japan).
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Crystal structure and LOF modeling
Protein purification methods are described in Supplemental materials. The S. aureus COL
MnaA protein sample concentrated at 31 mg ml-1 was screened for crystallization by free inter-
face diffusion using Topaz nano-chips. The crystallization condition most readily transferable
to a set-up by vapor diffusion contained 0.1M Na Cacodylate, pH 6.5, 0.1M Li2SO4, 30% PEG
400. However the reproducibility of the experiments was poor and the crystals when they grew
had often poor diffraction not exceeding 4–6 Å. Structure determination using the best crystal
showed that UDP is present bound to the protein in the crystal, although no exogenous UDP
was ever added to the protein sample at any step during protein purification or crystallization.
Crystallization reproducibility and crystal diffraction were subsequently significantly improved
by adding Na2UDP from a 200 mM stock solution to the protein sample right before crystalli-
zation set-up to a final ligand concentration of 4 mM. The final optimized conditions were 0.1
M Tris Cl pH 8.0, 0.1M Na2SO4, 52% PEG 400 at a temperature of 22°C, adding 1.5 μl precipi-
tant to 1.5 μl protein and let equilibrate by vapor diffusion against precipitant in a hanging
drop set-up. For diffraction experiments the crystals were harvested from the crystallization
drop and directly frozen in a bath of liquid nitrogen.
The crystals grow in space group P 21 21 21, a = 55.5Å, b = 85.8Å, c = 168.8Å with two mole-
cules per asymmetric unit and diffract up to 1.9Å. The data were collected at the Canadian
Light Source 08ID-1 beam line on a Mar mosaic CCD300 CCD detector (Canadian Light
Source, Saskatoon, Saskatchewan, Canada). The diffraction data were processed, reduced and
merged using the autoPROC automated pipeline with calls to the XDS software for indexing
and integration, and the package AIMLESS for scaling and merging. The structure was solved
by molecular replacement with the MOLREP program using PDB entry 1F6D as a starting
point. The model was first refined with autoBUSTER, then rebuilt with the sequence switched
to the S. aureus sequence using the COOT graphical suite. The structure was compared with
one rebuilt at that point with the Phenix automated AutoBuild procedure and some results
obtained with the latter incorporated in the model. The UDP ligand was added in a difference
“omitmap” (i.e. the ligand was always excluded from the model prior to generating this map).
After several cycles of refinement using autoBUSTER and rebuilding with COOT the final
models contains all residues except residues 38 to 43, 60 to 67, and from 376 to the C-terminal
residue in one copy of the molecule in the asymmetric unit, and 60 to 67, and from 376 to the
C-terminal end in the other. The model also contains one molecule of UDP per chain, 185
waters, and 3 sulfate anions. It refines to a final crystallographic Rwork and Rfree values of 20.4%
and 22.7%, respectively, and presents good stereochemistry according to the programMol-
probity. The model and structure factors have been deposited in the Protein Data Bank with
code 5ENZ.
NMR binding experiments
Tunicamycin binding was detected by saturation transfer difference (STD) NMR. 15 μM tuni-
camycin was added into 500 μl binding buffer [25 mM Tris(d11)-DCl (pD 8.0), 50 mM NaCl
and 25 μMTSP (2,2,3,3-Tetradeutero-3(trimethylsilyl)propionic acid) in 99.98% D2O] which
contained either 5 μM 2-epimerase (MnaA/Cap5P) or no protein as a negative control. The
binding mixture was incubated for 2 hours at 25°C before NMR data collection. STD NMR
spectra were collected at 298 K on a Bruker 600 MHz Avance spectrometer (Bruker, Billerica,
Massachusetts, USA) equipped with a 5 mm TXI cryogenic probe. Selective saturation of the
protein was applied by switching the on-and off-resonance saturation frequency after each
scan. A train of Gaussian shape pulses with 50 ms pulse length (corresponding to an excitation
width of 100 Hz) separated by a delay of 1ms was used, with the total length of the selective
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saturation set to 3s, and the on-and off-resonance saturation frequencies set to -120 Hz and
20,000 Hz, respectively. A total time of 50 minutes was required to collect a single STD NMR
spectrum including sample changing. The STD NMR experiment was repeated on a solution of
tunicamycin in the absence of protein to exclude any artifacts and make sure the observed STD
NMR signals are due to tunicamycin binding to 2-epimerase.
Assays for enzymatic activity of MnaA
MnaA-catalyzed interconversion of UDP-GlcNAc and UDP-ManNAc was carried out in a
total volume of 50 μl containing either UDP-GlcNAc or UDP-ManNAc (0–3 mM as indicated)
in 10 mMNaPi, 50 mMNaCl, pH 8.0. Reactions were initiated by the addition of 0.109 μg
MnaA-His6 (forward reaction, FW) or 0.327 μg MnaA-His6 (reverse reaction, RV) and incu-
bated for 10 min to 5 h at 30°C. All enzymatic reactions were quenched by heating (10 min,
100°C) and analyzed by capillary electrophoresis. Tunicamycin (Sigma Aldrich, Munich, Ger-
many) was added at concentrations ranging from 0 to 200 μM. Reactions were stopped by heat-
ing after 120 min (10 min, 100°C).
Supporting Information
S1 Text. Supporting materials and methods. Detailed description of materials, methods, sup-
porting references and supporting Tables A-C.
(DOCX)
S1 Fig. MnaA loss of function mutants in MRSA and MRSE fail to produce WTA.WTA
extraction and SDS PAGE analysis fromMRSA COL mutants (left) and L638R MRSE
CLB26329 (right). Note, wild-type MRSAWTA polymers appear as a ladder of discretely sized
bands whereas a more diffuse staining of MRSEWTA polymer is observed. WTAmaterial was
normalized to cell biomass prior to loading. The tarOSa
Y95 deletion mutant serves as a control
for complete impairment of WTA polymer production. Deletion of cap5P did not noticeably
affect WTA production.
(TIF)
S2 Fig. Cap5P and MnaA share a high degree of homology, and only MnaA is present in S.
epidermidis. (A) Alignment of MRSA COLMnaA and Cap5P and MRSE CLB26329 MnaA
demonstrates high degrees of sequence identity and similarity. Black shading represents identi-
cal and grey is similar using default consensus settings with the BOXSHADE program (http://
sourceforge.net/projects/boxshade/). (B) Alignment of MRSA COLMnaA with its closest
human homolog, GNE2. GNE2 has 2 domains, the N-terminal part in its longest isoform
shows 22% sequence identity. Alignment was done in Clustal Omega program [S12]. An aster-
isk indicates positions which have a single, fully conserved residue. A colon indicates conserva-
tion between groups of strongly similar properties—scoring> 0.5 in the Gonnet PAM 250
matrix. A period indicates conservation between groups of weakly similar properties—scoring
=< 0.5 in the Gonnet PAM 250 matrix.
(TIF)
S3 Fig. Generation of cap5P deletion mutant in MRSA COL. (A) Suicide plasmid pSAKO
was modified for replication in S. aureus by cloning the temperature sensitive replicon repF
from plasmid pAUL-A, into the Sac1 restriction site, yielding pSAKOTS. (B) To create the zira-
cin resistance cassette using 3-way PCR, the emtA gene was PCR amplified from plasmid
pPAM19 with primers 1700+1701. Approximately 1 kB of cap5P upstream sequence was PCR
amplified from MRSA COL with primers 1702+1704, appending an Aatll restriction site. Simi-
larly, cap5P downstream sequence was amplified with primers 1703+1646, appending a Bglll
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site. (C) The 3 fragments of the cap5P::emtA cassette were stitched together using primers 1704
+1646, restriction digested with Aatll and Bglll, then ligated and cloned into pSAKOTS, yielding
the final cap5P::emtA knockout plasmid.
(TIF)
S4 Fig. Representative growth curves of MRSA COL and MRSE CLB26328 epimerase
mutants. Growth in 20 mL cultures was monitored by viable counts at 0, 2, 4, 6 and 24 hours.
(A) Growth of COL mutants Δcap5P and Δcap5P mnaASa
P12L in Mueller Hinton broth com-
pared to ΔtarO and isogenic parent control strain. (B) Growth of Δcap5P mnaASa
P12L in MH
broth + Chloramphenicol (CAM) 20 μg mL-1 and 0.5% xylose complemented by pEPSA5 vec-
tor alone or with pEPSA5 carryingmnaASa or cap5P. (C) Growth of MRSE CLB26329 mutants
(indicated) in LB broth and mutant complements in LB broth supplemented with CAM 20 μg
mL-1 and 0.5% xylose.
(TIF)
S5 Fig. MRSA COLmnaA, Δcap5P and double mutants display morphological defects con-
sistent with WTA depletion. Structured illumination microscopy images of cells incubated
with (A) Van-FL, and (B) Nile Red to label the cell wall and membrane, respectively. COL
ΔtarOmutants lacking WTA show increased cell size heterogeneity, abnormal septal place-
ment and cell separation defects (arrows), similar to the defects that result from the deletion of
both epimerases. COL Δcap5Pmutants show a wild-type morphology. Scale bars represent
1 μm.
(TIF)
S6 Fig. MRSEmnaAmutants display morphological defects consistent with WTA deple-
tion. Structured illumination microscopy images of cells incubated with (A) Van-FL, and (B)
Nile Red to label the cell wall and membrane, respectively. Mutants lacking WTA show
increased cell size heterogeneity and septum placement defects (arrows). Scale bars represent
1 μm.
(TIF)
S7 Fig. Imipenem is bactericidal against MRSA and MRSE lacking WTA 2-epimerase func-
tion. All strains were grown in the presence of 4 μg ml-1 imipenem (IPM) and CFUs measured
over 24 hours. (A) MRSA COL and Δcap5P are unaffected by imipenem (4 μg ml-1), while the
Δcap5P mnaASa
P12L mutant displays a 3 log reduction in cell viability within 7 hr of imipenem
treatment. Plasmid-based copies of wild-type cap5P (pcap5P),mnaASa (pmnaASa), and
mnaASe (pmnaASe) restore resistance to imipenem. (B) Kill curves of MRSE CLB26329 per-
formed as in (A) usingmnaASe
ΔY151 and 4 μg ml-1 imipenem plasmid-based copies of wild-
type cap5P (pcap5P),mnaASa (pmnaASa), andmnaASe (pmnaASe) fully restore resistance to
imipenem.
(TIF)
S8 Fig. WTA is required for biofilm formation in MRSA.MRSA COL biofilms were grown
in triplicates for 24 hours in 96-well black clear bottom plates with or without indicated sub-
MIC concentrations of WTA inhibitors. Isolation and characterization of MRSA COL tarO,
tarA, tarB, tarD, and tarI LOF mutants were described previously [34] and assayed here to
broaden conclusions concerning the requirement of WTA in biofilm formation. Δpbp3, Δpbp4,
and Δpbp3, Δpbp4 double mutants are included as negative controls for the biofilm assay. Tuni-
camycin and L638 treatments were performed at the indicated sub-MIC drug concentrations.
Genetic complementation of described mutants was performed using plasmid-based copies of
wild-type cap5P (pcap5P),mnaASa (pmnaASa), andmnaASe (pmnaASe) as indicated. Biofilms
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were stained with BacLight Green fluorescent stain. Z-stacks were obtained at 60x magnifica-
tion. Scale bar = 10 μm.
(TIF)
S9 Fig. WTA is required for biofilm formation in MRSE.MRSE CLB26329 biofilms were
grown in triplicates for 24 hours in 96-well black clear bottom plates with or without indicated
sub-MIC concentrations of WTA inhibitors. Isolation and characterization of MRSE tarO, and
tarA LOF mutants were described previously [34] and assayed here to broaden conclusions
concerning the requirement of WTA in biofilm formation. Tunicamycin and L638 treatments
were performed at the indicated sub-MIC drug concentrations. Genetic complementation of
described mutants was performed using plasmid-based copies of wild-type cap5P (pcap5P),
mnaASa (pmnaASa), andmnaASe (pmnaASe) as indicated. Biofilms were stained with BacLight
Green fluorescent stain. Z-stacks were obtained at 60x magnification. Scale bar = 10 μm.
(TIF)
S10 Fig. Inhibition of WTA biosynthesis cannot kill preformed biofilms. To assess biofilm
killing by WTA inhibitors alone or in combination with imipenem at its clinical breakpoint,
MRSA COL (A) and MRSE CLB26329 (B) biofilms were grown for 24 hours in 96-well plates
before addition of WTA inhibitors tunicamycin (tuni), L638, in the absence or presence of imi-
penem (IPM), and then incubated for an additional 24 hours. Note drug concentrations of
each inhibitor used are shown in parentheses as μg/ml. Biofilms were stained with Syto 10 for
total cell staining and DEAD Red for membrane-damaged cells. Y-axis measures dead/live cell
ratio. Error bars are standard deviations from triplicate experiments. No effect of any com-
pounds tested alone or in combination was observed.
(TIF)
S11 Fig. Representative capillary electropherogram of the MnaA-catalyzed interconversion
of UDP-GlcNAc and UDP-ManNAc. Peaks, λmax = 260 nm: 1 buffer; 2 internal standard (I.
S.) adenosine; 3 UDP-ManNAc; 4 UDP-GlcNAc.
(TIF)
S12 Fig. Enzyme kinetics of the MnaA-catalyzed interconversion of UDP-GlcNAc and
UDP-ManNAc. (A) Michaelis-Menten plot for MnaA forward reaction, Km for UDP-GlcNAc:
411 ± 57 μM, Vmax: 0.171 ± 0.037 μmol/min/mg protein; (B) Michaelis-Menten plot for MnaA
reverse reaction, Km: 131 ± 21 μM, Vmax: 0.159 ± 0.021 μmol/min/mg protein.
(TIF)
S13 Fig. Methicillin-sensitive S. aureus RN4220 requires MnaA and Cap5P for WTA bio-
synthesis and biofilm formation. (A) WTA extraction and SDS PAGE analysis fromMSSA
RN4220 ΔmnaA and ΔmnaA Δcap5P. Note, wild-type MSSA RN4220 WTA polymers appear
as a ladder of discretely sized. WTA material was normalized to cell biomass prior to loading.
Deletion ofmnaA alone does not affect WTA levels, whereas the double deletion ofmnaA and
cap5P does. (B) For total biofilm quantification, biofilms were grown in triplicates for 24 hours
in 96-well plates. Biofilms were stained with safranin and dissolved in glacial acetic acid before
OD564 was measured. Bars represent mean OD, error bars represent standard deviation. Note
that deletion ofmnaA alone does not affect biofilm, whereas the double deletion ofmnaA and
cap5P does (C) MIC values of penicillin G, tetracycline, and L638. Note that deletion ofmnaA
alone does not confer resistance to TarG inhibitor L638, whereas the double deletion ofmnaA
and cap5P does.
(TIF)
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